Literature DB >> 15201851

Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia.

C Beretta, G Gaipa, V Rossi, S Bernasconi, O Spinelli, M G Dell'Oro, C Rizzari, A Rambaldi, A Biondi, G Cazzaniga.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15201851     DOI： 10.1038/sj.leu.2403409

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  4 in total

Review 1.  FLT3-ITD and its current role in acute myeloid leukaemia.

Authors:  Francisco Alejandro Lagunas-Rangel; Venice Chávez-Valencia
Journal:  Med Oncol       Date:  2017-05-03       Impact factor: 3.064

2.  FLT3-ITD in Children with Early T-cell Precursor (ETP) Acute Lymphoblastic Leukemia: Incidence and Potential Target for Monitoring Minimal Residual Disease (MRD).

Authors:  Luca Lo Nigro; Nellina Andriano; Barbara Buldini; Daniela Silvestri; Tiziana Villa; Franco Locatelli; Rosanna Parasole; Elena Barisone; Anna Maria Testi; Andrea Biondi; Maria Grazia Valsecchi; Carmelo Rizzari; Valentino Conter; Giuseppe Basso; Giovanni Cazzaniga
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 3.  Minimal residual disease quantitation in acute myeloid leukemia.

Authors:  David Shook; Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana
Journal:  Clin Lymphoma Myeloma       Date:  2009

Review 4.  How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet.

Authors:  Marie C Béné; Jaspal S Kaeda
Journal:  Haematologica       Date:  2009-07-07       Impact factor: 9.941
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.